FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		Table I - Non	-Derivative Securities Acquired, Disposed of, or Bene	ficially Owned				
(City)	(State)	(Zip)						
WALTHAM	MA	02453		Form filed by More than One Reporting Person				
(Street)	GAD, SOTTE TI		4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applica X Form filed by One Reporting Person					
(Last) 95 SAWYER R	(First)	(Middle)	05/14/2024	below) below)				
			3. Date of Earliest Transaction (Month/Day/Year)	Officer (give title Other (specify				
1. Name and Addre	ss of Reporting Per BARRY M	rson [*]	2. Issuer Name and Ticker or Trading Symbol <u>Checkpoint Therapeutics, Inc.</u> [CKPT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
10b5-1(c). See In	struction 10.							

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 7. Nature of 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership Form: Direct (D) Date Execution Date. Transaction Securities Indirect (Month/Day/Year) Code (Instr. Beneficially Owned or Indirect (I) Beneficial if any Following Reported Transaction(s) (Month/Dav/Year) 8) (Instr. 4) Ownership (Instr. 4) (A) or (Instr. 3 and 4) Code v Price Amount D) COMMON STOCK 05/14/2024 A 32,051(1) \$0.00 67,174(2) D Α 50,000(3) 117,174(2) COMMON STOCK **\$0.00** 05/14/2024 Α А D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported	or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

Explanation of Responses:

1. The 32,051 shares of restricted Common Stock will vest on May 14, 2027, subject to Mr. Salzman's continued service on the board on such date.

2. Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Salzman's continued service on the board.

3. The 50,000 shares of restricted Common Stock will vest according to the following schedule, subject to Mr. Salzman's continued service on the board on each date: one third on May 14, 2027, one third on May 14, 2028, and one third on May 14, 2029.

/s/ James F. Oliviero, Attorney-in- 05/16/2024

** Signature of Reporting Person

Fact

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.